All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
with Sagar Lonial, Naresh Bumma, Amrita Krishnan, and Sergio Giralt
Monday, March 11, 2024 | 8:00 am EST
This independent educational activity is supported by Janssen. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
EloPd for the treatment of RRMM: Real-world efficacy and safety data
Here, we summarize a publication by Gentile et al. on real-world experiences and outcomes in patients with RRMM treated with EloPd compared with clinical trial data from ELOQUENT-3.
What are the latest updates on trispecific antibodies for the treatment of MM?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne...